Valeo Pharma Inc. (TSE:VPH) to Post Q1 2024 Earnings of ($0.08) Per Share, Echelon Wealth Partners Forecasts

Valeo Pharma Inc. (TSE:VPHFree Report) – Equities research analysts at Echelon Wealth Partners dropped their Q1 2024 earnings per share (EPS) estimates for Valeo Pharma in a research note issued on Monday, February 5th. Echelon Wealth Partners analyst S. Quenneville now expects that the company will earn ($0.08) per share for the quarter, down from their previous estimate of ($0.06). Echelon Wealth Partners also issued estimates for Valeo Pharma’s Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.04) EPS and FY2024 earnings at ($0.21) EPS.

Valeo Pharma Stock Up 11.1 %

VPH opened at C$0.20 on Thursday. The business has a fifty day moving average of C$0.23 and a 200 day moving average of C$0.24. Valeo Pharma has a 52-week low of C$0.13 and a 52-week high of C$0.60. The stock has a market cap of C$19.73 million, a P/E ratio of -0.63 and a beta of 2.62.

About Valeo Pharma

(Get Free Report)

Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.

Read More

Receive News & Ratings for Valeo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.